Supernus Pharmaceuticals Inc (SUPN)
Fixed asset turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 661,817 | 607,521 | 673,056 | 560,079 | 500,962 |
| Property, plant and equipment | US$ in thousands | 11,545 | 13,530 | 15,173 | 16,955 | 37,824 |
| Fixed asset turnover | 57.32 | 44.90 | 44.36 | 33.03 | 13.24 |
December 31, 2024 calculation
Fixed asset turnover = Revenue ÷ Property, plant and equipment
= $661,817K ÷ $11,545K
= 57.32
The fixed asset turnover ratio measures the efficiency of Supernus Pharmaceuticals Inc in generating sales revenue from its fixed assets.
Analyzing the trend of the fixed asset turnover ratio over the past five years, we observe a significant increase from 13.24 in December 31, 2020 to 57.32 in December 31, 2024. This indicates that the company has been able to generate higher sales relative to its investment in fixed assets over the years.
The substantial improvement in the fixed asset turnover ratio suggests that Supernus Pharmaceuticals Inc has been effectively utilizing its fixed assets to drive revenue growth. This could be attributed to better asset management, more efficient production processes, or effective utilization of existing assets to increase sales.
Overall, the increasing trend in the fixed asset turnover ratio reflects positively on the operational efficiency and productivity of Supernus Pharmaceuticals Inc in utilizing its fixed assets to generate sales revenue. It indicates improved effectiveness in capital utilization and a potential for sustained growth in the company's profitability.
Peer comparison
Dec 31, 2024